Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
No validated human dose
In the EU, supply and possession of unapproved peptides for purposes other than legitimate research can engage the Arzneimittelgesetz (AMG) and equivalent national medicines acts
Tirzepatide 5mg Tirzepatide 5mg early-escalation research vial common mid-low dose for incretin-pathway and metabolic research studies
Due to its dual-peptide profile, it is frequently examined in structured investigations focusing on signalling pathway interaction, recovery-response dynamics, and peptide stability within controlled research environments
Semaglutide leads the risk profile With a reporting odds ratio of 2.46 in the FAERS database, semaglutide carries the highest documented risk of alopecia among GLP-1 receptor agonists
US$ 27.60
US$ 22.11
US$ 26.74
US$ 24.60
